HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $110.
HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $110.